Global pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).
The single-injection, citrate-free maintenance dose will be offered in the United States through prefilled pen or prefilled syringe from early 2026.
This approval follows Omvoh's recent European Union authorisation for single-injection maintenance dosing for UC.
A Phase 1 study comparing one 200 mg/2 mL subcutaneous injection to two 100 mg/1 mL injections in patients confirmed that the product is bioequivalent to the earlier approved two-injection regimen.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval